Michael F. Press
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Press, Michael F.; Wolff, Antonio C.; Hammond, M. Elizabeth H.; Schwartz, Jared N.; Hagerty, Karen L.; Allred, D. Craig; Cote, Richard J.; Dowsett, Mitchell; Fitzgibbons, Patrick L.; Hanna, Wedad M.; Langer, Amy; McShane, Lisa M.; Paik, Soonmyung; Pegram, Mark D.; Perez, Edith A.; Rhodes, Anthony; Sturgeon, Catharine; Taube, Sheila E.; Tubbs, Raymond; Vance, Gail H.; Van De Vijver, Marc; Wheeler, Thomas M.; Hayes, Daniel F.
Authors
Antonio C. Wolff
M. Elizabeth H. Hammond
Jared N. Schwartz
Karen L. Hagerty
D. Craig Allred
Richard J. Cote
Mitchell Dowsett
Patrick L. Fitzgibbons
Wedad M. Hanna
Amy Langer
Lisa M. McShane
Soonmyung Paik
Mark D. Pegram
Edith A. Perez
Anthony Rhodes
Catharine Sturgeon
Sheila E. Taube
Raymond Tubbs
Gail H. Vance
Marc Van De Vijver
Thomas M. Wheeler
Daniel F. Hayes
Abstract
Purpose: To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an expert panel, which conducted a systematic review of the literature and developed recommendations for optimal HER2 testing performance. The guideline was reviewed by selected experts and approved by the board of directors for both organizations. Results: Approximately 20% of current HER2 testing may be inaccurate. When carefully validated testing is performed, available data do not clearly demonstrate the superiority of either immunohistochemistry (IHC) or in situ hybridization (ISH) as a predictor of benefit from anti-HER2 therapy. Recommendations: The panel recommends that HER2 status should be determined for all invasive breast cancer. A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed. Elements to reliably reduce assay variation (for example, specimen handling, assay exclusion, and reporting criteria) are specified. An algorithm defining positive, equivocal, and negative values for both HER2 protein expression and gene amplification is recommended: a positive HER2 result is IHC staining of 3+ (uniform, intense membrane staining of > 30% of invasive tumor cells), a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to chromosome 17 signals) of more than 2.2; a negative result is an IHC staining of 0 or 1+, a FISH result of less than 4.0 HER2 gene copies per nucleus, or FISH ratio of less than 1.8. Equivocal results require additional action for final determination. It is recommended that to perform HER2 testing, laboratories show 95% concordance with another validated test for positive and negative assay values. The panel strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored with the use of stringent laboratory accreditation standards, proficiency testing, and competency assessment. The panel recommends that HER2 testing be done in a CAP-accredited laboratory or in a laboratory that meets the accreditation and proficiency testing requirements set out by this document. Copyright © 2007 by the American Society of Clinical Oncology and College of American Pathologists. All rights reserved.
Citation
Press, M. F., Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., …Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology, 25(1), 118-145. https://doi.org/10.1200/JCO.2006.09.2775
Journal Article Type | Review |
---|---|
Publication Date | Jan 1, 2007 |
Journal | Journal of Clinical Oncology |
Print ISSN | 0732-183X |
Publisher | American Society of Clinical Oncology |
Peer Reviewed | Peer Reviewed |
Volume | 25 |
Issue | 1 |
Pages | 118-145 |
DOI | https://doi.org/10.1200/JCO.2006.09.2775 |
Keywords | breast cancer, human epidermal growth factor, receptor 2 testing |
Public URL | https://uwe-repository.worktribe.com/output/1030502 |
Publisher URL | http://dx.doi.org/10.1200/JCO.2006.09.2775 |
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search